{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:52:10Z","timestamp":1785775930118,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Alfa Wasserman SpA","award":["70\/3\/10733"],"award-info":[{"award-number":["70\/3\/10733"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12876-016-0484-6","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T08:30:42Z","timestamp":1468225842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage"],"prefix":"10.1186","volume":"16","author":[{"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouel","family":"Pyleris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Barbatzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Pistiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"484_CR1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-2036.2005.02690.x","volume":"22","author":"A Lupascu","year":"2005","unstructured":"Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:1157\u201360.","journal-title":"Aliment Pharmacol Ther"},{"key":"484_CR2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1365-2036.2005.02493.x","volume":"2","author":"G Nucera","year":"2005","unstructured":"Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, Cremonini F, Cammarota G, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2005;2:1391\u20135.","journal-title":"Aliment Pharmacol Ther"},{"key":"484_CR3","first-page":"2241","volume":"55","author":"ED Shah","year":"2010","unstructured":"Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2241\u20139.","journal-title":"Dig Dis Sci"},{"key":"484_CR4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/gut.2009.205476","volume":"60","author":"D Yu","year":"2011","unstructured":"Yu D, Cheeseman F, Vanner S. Combined oro-faecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-faecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334\u201340.","journal-title":"Gut"},{"key":"484_CR5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10620-012-2033-7","volume":"57","author":"E Pyleris","year":"2012","unstructured":"Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321\u20139.","journal-title":"Dig Dis Sci"},{"key":"484_CR6","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1365-2036.2011.04625.x","volume":"33","author":"RS Choung","year":"2011","unstructured":"Choung RS, Ruff KC, Maljotra A, Herrick L, Locke 3rd GR, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33:1059\u201367.","journal-title":"Aliment Pharmacol Ther"},{"key":"484_CR7","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMra1207068","volume":"367","author":"M Camillieri","year":"2012","unstructured":"Camillieri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367:1626\u201335.","journal-title":"N Engl J Med"},{"key":"484_CR8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","volume":"11","author":"WK Lo","year":"2013","unstructured":"Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11:483\u201390.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"484_CR9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11894-006-0051-3","volume":"8","author":"HR Lee","year":"2006","unstructured":"Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep. 2006;8:305.","journal-title":"Curr Gastroenterol Rep"},{"issue":"Suppl 2","key":"484_CR10","first-page":"1143","volume":"45","author":"WG Thompson","year":"1999","unstructured":"Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, M\u00fcller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45 Suppl 2:1143\u20137.","journal-title":"Gut"},{"key":"484_CR11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.12304","volume":"37","author":"C Jacobs","year":"2013","unstructured":"Jacobs C, Coss Adame E, Attaluri A, Valsetin J, Rao SSC. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and\/or fundal overgrowth. Aliment Pharmacol Ther. 2013;37:1103\u201311.","journal-title":"Aliment Pharmacol Ther"},{"key":"484_CR12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2362.2010.02419.x","volume":"41","author":"D Compare","year":"2011","unstructured":"Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, Romano M, Nardone G. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011;41:380\u20136.","journal-title":"Eur J Clin Invest"},{"key":"484_CR13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/apt.12479","volume":"38","author":"SC Shah","year":"2013","unstructured":"Shah SC, Day LW, Somsouk M, Sewell JJ. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38:925\u201334.","journal-title":"Aliment Pharmacol Ther"},{"key":"484_CR14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","volume":"364","author":"M Pimentel","year":"2011","unstructured":"Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22\u201333.","journal-title":"N Engl J Med"},{"key":"484_CR15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijantimicag.2013.12.008","volume":"43","author":"A Pistiki","year":"2014","unstructured":"Pistiki A, Galani I, Pyleris E, Barbatzas C, Pimentel M, Giamarellos-Bourboulis EJ. In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. Int J Antimicrob Agents. 2014;43:236\u201341.","journal-title":"Int J Antimicrob Agents"},{"key":"484_CR16","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","volume":"44","author":"ZD Jiang","year":"2000","unstructured":"Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205\u20136.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-016-0484-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:11:16Z","timestamp":1498313476000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-016-0484-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1186\/s12876-016-0484-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]},"article-number":"67"}}